HIFU for Focal Ablation of Prostate Tissue: An Observational Study
NCT: NCT03620786 · RECRUITING
Publicidad
Resumen breve
The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through clinical data and health-related quality of life (HRQOL) questionnaires.
Fuente oficial
Ver en ClinicalTrials.gov →Datos obtenidos de la API de ClinicalTrials.gov. Para conocer el estado más reciente, consulte el registro oficial.